We employed the CRISPR/Cas9 genome editing platform for the generation of the desired targeted genomic rearrangement in the A549 lung cancer ... a dose-response based assay monitored via IncuCyte ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results